Oculis a company developing among others CD-based ophthalmic formulations, the pioneer in applying GCD nanoparticles for drug delivery to the back of the eye, announces getting listed on Nasdaq.
This tells me that we have to believe in our inventions and ideas just as Thorsteinn Loftsson and Einar Stefansson did and be persistent in working on them. And that cyclodextrins have a bright future ahead 🙂
